相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Effect of Itraconazole and Its Metabolite Hydroxyitraconazole on the Blood Concentrations of Cyclosporine and Tacrolimus in Lung Transplant Recipients
Yuya Matsuda et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2022)
PharmVar GeneFocus: CYP3A5
Cristina Rodriguez-Antona et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1′-Hydroxylation and Testosterone 6β-Hydroxylation
Masaki Kumondai et al.
DRUG METABOLISM AND DISPOSITION (2021)
Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes
Delilah F. G. Hendriks et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Estimation of Blood Sirolimus Concentration Based on Tacrolimus Concentration/Dose Normalized by Body Weight Ratio in Lung Transplant Patients
Masafumi Kikuchi et al.
THERAPEUTIC DRUG MONITORING (2019)
Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers
Thomas Vanhove et al.
DRUG METABOLISM AND DISPOSITION (2018)
Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers
Jing Zhang et al.
THERAPEUTIC DRUG MONITORING (2017)
Lung Transplantation for Lymphangioleiomyomatosis in Japan
Katsutoshi Ando et al.
PLOS ONE (2016)
Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation
Takenori Niioka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis
Angelo M. Taveira-DaSilva Joel Moss
CLINICAL EPIDEMIOLOGY (2015)
Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies
L. Rojas et al.
PHARMACOGENOMICS JOURNAL (2015)
The Effects of CYP3A4 Induction and Inhibition on the Pharmacokinetics of Alisporivir in Humans
Avantika Barve et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)
CYP3A5*3 and POR*28 Genetic Variants Influence the Required Dose of Tacrolimus in Heart Transplant Recipients
Dorothea Lesche et al.
THERAPEUTIC DRUG MONITORING (2014)
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin
Sara K. Quinney et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients
Violette M. G. J. Gijsen et al.
PHARMACOGENOMICS (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Effect of CYP3A5 Expression on the Inhibition of CYP3A-Catalyzed Drug Metabolism: Impact on Modeling CYP3A-Mediated Drug-Drug Interactions
Yoshiyuki Shirasaka et al.
DRUG METABOLISM AND DISPOSITION (2013)
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Francis X. McCormack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin
Sara K. Quinney et al.
DRUG METABOLISM AND DISPOSITION (2010)
Clinical Impact of Polymorphisms of Transport Proteins and Enzymes Involved in the Metabolism of Immunosuppressive Drugs
C. Rosso Felipe et al.
TRANSPLANTATION PROCEEDINGS (2009)
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process
Shiew-Mei Huang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient
A Said et al.
PHARMACOTHERAPY (2006)
Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient
DR Kuypers et al.
TRANSPLANTATION (2005)
Role of itraconazole metabolites in CYP3A4 inhibition
N Isoherranen et al.
DRUG METABOLISM AND DISPOSITION (2004)
Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
A MacDonald et al.
CLINICAL THERAPEUTICS (2000)